Aripiprazole Tablet
Product Images NDC 0615-8375

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 0615-8375). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Aripiprazole Tabs 5mg 8375 Sciegen For Dr Redd 1)

Chemical structure of aripiprazole, showing its molecular framework with two chlorine atoms on a phenyl ring linked to a piperazine group and further connected to a quinolinone structure.*

FDA Label Image

Aripiprazole Tabs 5mg Bingo Card Label (Aripiprazole Tabs 5mg 8375 Sciegen For Dr Redd 10)

Multiple small labels for Aripiprazole Tablets USP 5 mg, each including the product name, strength, lot number, expiration date, and barcode. The labeler is Vangard Labs, Glasgow, KY. The larger left panel includes similar information with Dr. Reddy's as manufacturer and NCS HealthCare of KY, LLC dba Vangard Labs as the labeler. It also includes storage instructions and is marked for institutional use only, with quantity 30 indicated.*

FDA Label Image

Figure-1.jpg (Aripiprazole Tabs 5mg 8375 Sciegen For Dr Redd 2)

A chart showing the effect of other drugs on Aripiprazole pharmacokinetics, depicting fold change and 90% confidence intervals for AUC and Cmax values. The chart compares changes relative to a reference without interacting drugs, listing CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other interacting drugs.*

FDA Label Image

Figure-2.jpg (Aripiprazole Tabs 5mg 8375 Sciegen For Dr Redd 3)

A pharmacokinetic chart illustrating the effect of various drugs on Aripiprazole's metabolite, Dehydro-Aripiprazole, showing fold change and 90% confidence intervals. The horizontal axis represents change relative to reference, with points for inhibitors (CYP3A4, CYP2D6), inducers (CYP3A4), gastric acid blockers, and other drugs. The vertical axis lists drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam, showing their impact on AUC and Cmax values.*

FDA Label Image

Figure-3.jpg (Aripiprazole Tabs 5mg 8375 Sciegen For Dr Redd 4)

A pharmacokinetic chart titled 'Effect of Aripiprazole on Other Drugs' showing fold changes and 90% confidence intervals for various drugs metabolized by enzymes CYP2D6, CYP2C9, 2C19, UGT1A4, and others. The x-axis represents change relative to reference (without interacting drug), ranging from 0.5 to 3.0. The y-axis lists drugs including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, lorazepam, venlafaxine and its metabolite, and escitalopram with pharmacokinetic parameters AUC and Cmax indicated.*

FDA Label Image

Figure-4.jpg (Aripiprazole Tabs 5mg 8375 Sciegen For Dr Redd 5)

A pharmacokinetic chart showing Aripiprazole fold change and 90% confidence intervals in various special populations. The chart compares changes in AUC and Cmax for groups including CYP2D6 poor vs. extensive metabolizers, gender, age, hepatic impairment, and severe renal impairment relative to reference values.*

FDA Label Image

Figure-5.jpg (Aripiprazole Tabs 5mg 8375 Sciegen For Dr Redd 6)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing changes relative to reference in AUC and Cmax for factors including CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment. It displays fold change values with confidence intervals on the x-axis.*

FDA Label Image

Figure-6.jpg (Aripiprazole Tabs 5mg 8375 Sciegen For Dr Redd 7)

A line graph comparing the proportion of subjects with relapse over time between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. Two lines represent Aripiprazole (solid blue) and placebo (dashed red). A table below indicates the number of subjects at risk for each group at various time points.*

FDA Label Image

Figure 7 (Aripiprazole Tabs 5mg 8375 Sciegen For Dr Redd 8)

A line graph showing the proportion of subjects with relapse over days from randomization for a study comparing Aripiprazole and placebo. The x-axis represents days from randomization up to 182 days, with numbers of subjects at risk shown below. The y-axis shows the proportion with relapse from 0.0 to 1.0. Aripiprazole is represented by a solid blue line with lower relapse proportions, while placebo is depicted by a dashed red line with higher relapse proportions over time.*

FDA Label Image

Figure 8 (Aripiprazole Tabs 5mg 8375 Sciegen For Dr Redd 9)

A line graph comparing the proportion of subjects with relapse over time between Aripiprazole and placebo groups. The x-axis shows days from randomization (0 to 364), and the y-axis shows the proportion with relapse (0.0 to 1.0). Aripiprazole group is represented by a solid blue line, and the placebo group by a dashed red line. The graph includes the number of subjects at risk for each group at various time points below the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.